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 1. Introduction
Metronidazole  is  a  prodrug. Chemically  is  a  2-(2-methyl-5-nitroimidazol-1-yl),  ethanol  used  as  Antibiotic,  Amebicide1. 
Norfloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. Chemically is a 1-ethyl-
6-fluoro-4-oxo-7-piperazin-1-yl-1H-quinoline-3-carboxylic acid used in treatment of urinary tract of infection2.
Literature survey reveals that, UV, HPLC, Spectrophotometric method are reported for Metronidazole alone  and 
combination with other drugs3-10. UV, HPLC, Spectrophotometric method and simple electrolytical method are reported for 
Norfloxacin alone and combination with other drugs11-17. The chemical structure of Metronidazole and Norfloxacin are 
given below.
Figure 1: Chemical Structure of (a) Metronidazole and (b) Norfloxacin
  
a)                                                             (b)
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2. Materials and Methods
Metronidazole (METRO) and Norfloxacin (NOR) were gifted by Molecule Lab Pvt. Ltd. (Ahmedabad, Gujarat). 
All  chemical  and reagents  used were of  HPLC grade for HPLC analysis  and analytical  grade for  spectroscopic study.  
Commercial pharmaceutical suspension preparation was claimed to contain 100mg/5ml of Metronidazole and 100mg/5ml of 
Norfloxacin. 
2.1 Instrument and Reagents
High performance liquid chromatography YL 9100 with PDA detector was used.Mobile phase comprising of was 
Triethylamine: 0.02 M Potassium Dihydrogen phosphates (pH 3.5): Methanol (0.01:70:30) at flow rate of 1ml/min was 
performed on C18 column (250mm × 4.6mm, 5µ).The effluent was detected at 292nm.The retension times of Metronidazole 
and norfloxacin were 6.10 and 3.50 min. The volume of injection was 20µl.
2.2 Selection of mobile phase
Sr. No. Mobile Phase Inference
1 Methanol : Water (50 : 50) 1st Peak showed fronting 
2 Acetonitrile : Water (50 : 50) 1st Peak showed fronting
3 0.02M Potassium Dihydrogen phosphate(pH 4.5) : Methanol (50 : 50)
Less resolution with tailing
4 0.02M Potassium Dihydrogen phosphate(pH 4.5) : Methanol (60:40)
Both peak resolve but with tailing
5 0.02M Potassium Dihydrogen phosphate(pH 3.5) : Methanol (60:40) 
Both peak resolve but 1st peak come at solvent level
6 Triethylamine : 0.02M Potassium Dihydrogen phosphate (pH 3.5) : Methanol(0.01:70:30)
Well resolved peaks with good shape
2.3 Preparation of Mobile phase
2.72gm of Potassium Dihydrogen Phosphate was weighed and dissolved it in to 500ml of HPLC water. Volume  
was made upto 1000ml with water. The final pH 3.5was adjusted using O-Phosphoric Acid. Finally composition of mobile 
phase was Triethylamine: 0.02 M Potassium Dihydrogen phosphates (pH 3.5): Methanol (0.01:70:30). The prepared mobile 
phase was filter through 0.45µm membrane filter paper. 
2.4 Standard Stock Solution
An accurately weighed quantity of standard MET (50 mg) and NOR (50 mg) powder were transferred to 50 ml 
volumetric flasks. Both drugs were dissolved in 30 ml of mobile phase. The flasks were shaken and sonicated for 15min and 
volumes were made up to mark with mobile phase. 25 ml of resulting solution was transferred in 100 ml volumetric flask 
and made up to mark with mobile phase to get 250 μg/ml MET and NOR solution. Linearity was determined in the range of 
12.5-37.5µg/ml for MET and NOR.
2.5 Assay in formulation
Accurately measured 1.25 ml of Metronidazole and Norfloxacin suspension was transferred to 50 ml volumetric 
flask and dissolved in 30 ml of mobile phase. The flask was shaken and sonicated for 5 min and volumes were made up to  
mark with mobile phase to get 100 μg/ml. The sample solution was further diluted with mobile phase to obtain the final  
concentration of 25μg/ml for each.
3. Result and Discussion
To optimize the RP-HPLC parameters, several mobile phase combination were tried. A satisfactory separation and  
good peak  symmetry was  found in  a  mixture  of  Triethylamine:  0.02  M Potassium Dihydrogen  phosphates  (pH 3.5):  
Methanol (0.01:70:30) at flow rate 1ml/min proved to be better than the other mixture in terms of resolution and peak shape. 
The optimum wavelength for detection was set at 292nm at which much better detector responses for both drug were 
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obtained. As show in Fig. 2, the retention times were 6.10 min for Metronidazole and for 3.50 min for Norfloxacin. The 
optical regression characteristics and validation parameters are showed in table 1.
Table 1: Optical regression characteristics and Validation parameters
Figure 2: Chromatogram for Metronidazole (25 μg /ml) and Norfloxacin (25 μg/ml)
3.1 Method validation
3.1.1 Linearity
The linearity of the response for MET and NOR was determined by preparing and injecting standard solutions of  
12.5-37.5μg/ml MET and 12.5-37.5μg/ml NOR. The calibration curves of MET and NOR (5 replications) showed in Figure  
4.9 and 4.10 respectively indicate that the response was linear over the concentration range. Correlation coefficient (r) was  
found 0.998 for MET and 0.999 for NOR as shown in Figure 3 and 4 respectively. The calibration curve was obtained by 
plotting absorbance(y axis) → concentrations(x axis).
Figure 3: Calibration curve of Metronidazole
Parameters MET NOR
Calibration range (μg/ml) 12.5-37.5 12.5-37.5 
Regression Equation (y = mx + c) y = 129.3x + 31.83 y = 78.84x + 14.53
Quantitation limit (μg/ml) 3.980 3.245
Detection limit (μg/ml) 1.313 1.071
Slope(m) 129.3 78.84
Intercept(c) 31.83 14.53
Correlation coefficient(r) 0.998 0.999
Intraday RSD* % 0.53-1.27 0.49-1.28
Interday RSD*% 0.76-1.59 0.97-1.54
Norfloxacin
Norfloxacin
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Figure 4: Calibration curve of Norfloxacin
3.1.2 Accuracy
Accuracy was performed at 50%, 100% and 150% levels by Standard addition method. Each concentration was 
analyzed 3 times and average recoveries were measured as shown in Table 2.
Table 2: Recovery studies of Metronidazole and Norfloxacin
Drug Level Amount taken(μg/ml)
Amount added
(μg/ml)
Total Amount
(μg/ml)
Amount found*
(μg/ml)
% Recovery ± S.D. 
(n=3)
MET
50% 10 5 15 14.99 99.93±0.048
100% 10 10 20 19.98 99.9±0.23
150% 10 15 25 25.034 100.13±0.23
NOR
50% 10 5 15 14.89 99.26±0.050
100% 10 10 20 19.87 99.35±0.22
150% 10 15 25 24.95 99.8±0.31
3.1.3 Limit of Detection and Quantification 
It is the lowest amount of analyte in a sample that can be detected but not necessarily quantitated under the stated 
experimental conditions. The detection limit(LOD) and quantification limit (LOQ) may be expressed as:
LOD = 3.3 × N/S 
LOQ = 10 × N/S 
Where, N is the standard deviation of the peak areas of the drug and S is the slope of the corresponding calibration curve. 
Limit of Detection for MET and NOR was found to be 1.313µg/ml and 1.071µg/ml respectively.
Limit of Quantitation for MET and NOR was found to be 3.980µg/ml and 3.245µg/ml respectively.
3.1.4 Precision
The precision of the method was demonstrated by inter-day and intra-day variation studies. Intraday precision was  
determined by analyzing MET and NOR three times in the same day. Inter day precision was determined by analyzing both 
the drugs three successive days. 
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Table 3: Precision study of Metronidazole
Conc.
(μg/ml)
Intraday
Mean ± S.D (n=3) %RSD
Interday
Mean ± S.D (n=3) %RSD
12.5 1656.69±19.23 1.16 1645.043±24.21 1.47
25 3272.42±41.83 1.27 3253.49±24.88 0.76
37.5 4808.87±25.87 0.53 4894.75±77.99 1.59
Table 4: Precision study of Norfloxacin
Conc.
(μg/ml)
Intraday
Mean ± S.D (n=3) %RSD
Interday
Mean ± S.D (n=3) %RSD
12.5 1008.81±5.01 0.49 1004.40±9.75 0.97
25 1990.50±25.52 1.28 2002.19±24.82 1.23
37.5 1990.68±30.37 1.01 2977.72±46.07 1.54
3.1.5 Robustness 
Robustness was carried by varying experimental parameters of proposed method. In case of liquid chromatography 
typical variations are the pH of the mobile phase, the mobile phase composition, and flow rate. No significant change was  
observed.
Table 5: Robustness parameter of Metronidazole and Norfloxacin.
Factor Value
AREA
MET NOR
Ph
3.3 3252.26 2020.37
3.5 3308.81 2012.494
3.7 3312.06 1992.90
Mean±S.D. 3291.033± 33.61 2008.59± 14.14
%R.S.D. 1.021 0.704
Mobile phase
Triethylamine: 0.02M Potassium Dihydrogen phosphate (pH 3.5) : 
Methanol (0.01:68:32) 3341.905 2042.219
Triethylamine: 0.02M Potassium Dihydrogen phosphate (pH 3.5) : 
Methanol (0.01:70:30) 3308.81 2012.494
Triethylamine: 0.02M Potassium Dihydrogen phosphate (pH 3.5) : 
Methanol (0.01:72:28) 3289.293 1997.092
Mean±S.D. 3313.33± 26.59 2017.26±22.93
%R.S.D. 0.802 1.13
Flow rate
0.9 3367.71 2049.67
1 3308.81 2012.494
1.1 3279.78 1988.28
Mean±S.D. 3318.76± 44.80 2016.81±30.92
%R.S.D. 1.34 1.53
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3.2 Assay of Pharmaceutical dosage form
One brands of MET and NOR combination was estimated and results are shown in Table 6.
Table 6: Analysis of marketed formulation
Formulation
MET NOR
Amount
Labelled
(mg)
Amount
Found*
(mg)
%Amount
Found ± S.D
(n=3)
Amount
labeled
(mg)
Amount
Found*
(mg)
% Amount
Found ± S.D
(n=3)
Brand I 100 99.95 99.95±0.93 100 101.73 101.73±0.75
3.3 System suitability testing 
System suitability test parameters like Resolution, Retention Time, Theoretical plate and Tailing factor are shown 
in Table 7.
Table 7: System suitability parameters of RP-HPLC method
Parameters MET NOR
Retention Time 6.10 3.50
Theoretical plate 2568 4246
Tailing factor 1.352 1.667
Resolution 7.444
4. Conclusion
All  these  factors  lead  to  conclude  that  the  proposed  method  is  accurate,  precise,  rapid  and  can  be  applied  
successfully for the estimation of MET and NOR in suspension without interference and with good sensitivity.
Reference
1. “Metronidazole Introduction”, September 2012 http://www.drugbank.ca/drugs/DB00916
2.  “Norfloxacin Introduction”, September 2012 http://www.drugbank.ca/drugs/DB01059
3. Mishra AK, Yadava R, Mishra A, Verma A, Chattopadhyay P, “Development and validation of U.V. spectrophotometric  
method for the determination of Metronidazole in tablet formulation” Int. J. Pharma Res. Dev. 2010, 2(6), 1-5.
4. Thulasamma  P  and  Venkateswarlu  P,  “Spectrophotometric  method  for  the  determination  of  Metronidazole  in  
pharmaceutical pure and dosage forms” Rasayan J. Chem. 2009, 2(4), 865-869.
5. Farhadi K and Bahar S, “Kinetic-Spectrophotometric determination of Metronidazole Benzoate in surfactant medium” 
J. Indian Chem. Soc. 2007; 54, 1521-1527.
6. Hassan  S,  Hussain  S,  Ansari  MT,  “Quantitation  of  Metronidazole  in  pharmaceutical  suspension  using  High 
Performance Liquid Chromatographic method” Pakistan J. Zool., 2011; 43(5), 909-914.
7. Patel S, “Development and Validation of HPLC method for simultaneous estimation of Ofloxacin and Metronidazole 
from pharmaceutical formulation” Int. J. Pharmaceut. Fro. Res., 2011; 1(2), 68-74.
8. Mishal A and Sober D, “Stability indicating reversed-phase liquid chromatographic determination of Metronidazole  
Benzoate and Diloxanide Furoate as bulk drug and in suspension dosage form” J. Pharm. Biomed. Anal. 2005, 39(4), 
819–823.
9. Vega E,  Dabbene V,  Nassetta  M, Sola N,  “Validation of a  reversed-phase LC method for  quantitative analysis  of 
intravenous admixtures of Ciprofloxacin and Metronidazole” J. Pharm. Biomed. Anal. 1999, 21(5), 1003-1009.
Trivedi et al / International Journal of Advances in Pharmaceutics  2 (1) 2013                                                                  11 
10. Gattavecchia E, Tonelli D, Breccia A, “Determination of Metronidazole, Misonidazole and its metabolite in serum and 
urine on rp-18 high-performance thin-layer chromatographic plates” J. Chrom. B, 1981; 224(3), 465-471.
11. Singh S,Inamullah, Sharma S, Yadav AK, Gautam H, “Estimation of Norfloxacin in tablet dosage form by using UV-
visible spectrophotometer” Der Pharmacia Lettre, 2012; 4(6), 1837-1842,.
12. Boonme P, Phadoongsombut N, Ingkatawornwong S, Faroongsarng D, “The Formulation Development and Stability 
Study of Norfloxacin Suspension” Thammasat Int. J. Sc. Tech., 2002; 7(1), 1-4.
13. Sher M, Hussain MA, Mehmood MH, Hassan MN, Bashir S, “Bioequivalence of Norfloxacin by HPLC-UV method” J.  
Chil. Chem. Soc. 2010, 55(2), 203-205.
14. Rege  PV,  Sathe  PA,  Salvi  VS,  “A simple  electroanlytical  method  for  estimation  of  Norfloxacin and  Tinidazole 
individually from pharmaceutical formulation” Res. J. Pharm. Bio. Che. Sci. 2011, 2(2), 495-505.
15. Kassab NM, Singh AK, Kedor-Hackmam ERM, Santoro MIRM, “Quantitative determination of Ciprofloxacin and 
Norfloxacin in Pharmaceutical preparations by high performance liquid chromatography”  Braz. J. Pharm. Sci. 2005, 
41(4), 507-513.
16. Morton SJ, Shull VH, Dick JD, “Determination of Norfloxacin and Ciprofloxacin concentrations in serum and urine by 
high-pressure liquid chromatography” Antimicrob. Agents and Chemother., 1986 30(2), 325-327.
17. Sebaiy MM, El-Shanawany AA, Adl SM, Abdel-Aziz LM, Hashem HA, “Rapid RP-HPLC method for simultaneous 
estimation of Norfloxacin and Tinidazole in tablet dosage form” AJP. Ana. 2011, 1(4), 79-84.
